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The pathophysiology of the diabetic kidney (e.g.,
hypertrophy, increased urinary albumin excretion (UAE)) is
still ill-defined. Parathyroid hormone-related protein (PTHrP)
is overexpressed in several nephropathies, but its role
remains unclear. We evaluated the effect of high glucose on
PTHrP and the PTH1 receptor (PTH1R) protein (by Western
blot and immunohistochemistry) in the kidney of mice with
streptozotocin-induced diabetes, and in several mouse renal
cells in vitro. Diabetic mice showed a significantly increased
renal expression of PTHrP and PTH1R proteins within 2–8
weeks from the onset of diabetes. These animals exhibited an
intense immunostaining for both proteins in the renal
tubules and glomeruli. Using transgenic mice overexpressing
PTHrP targeted to the renal proximal tubule, we found a
significant increase in the renal hypertrophy index and in
UAE in these diabetic mice relative to their control
littermates. Moreover, logistic regression analysis showed a
significant association between both PTHrP and PTH1R
protein levels and UAE in all diabetic mice throughout the
study. High-glucose (25 mM) medium was found to increase
PTHrP and PTH1R in tubuloepithelial cells, mesangial cells,
and podocytes in vitro. Moreover, this increase in PTHrP (but
not that of PTH1R) was inhibited by the AT1 receptor
antagonist losartan. Collectively, these results indicate that
the renal PTHrP/PTH1R system is upregulated in
streptozotozin-induced diabetes in mice, and appears to
adversely affect the outcome of diabetic renal disease. Our
findings also suggest that angiotensin II might have a role in
the PTHrP upregulation in this condition.
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In diabetes mellitus, nephropathy – the most common single
cause of end-stage renal disease in developed countries –
occurs related to a poor glycemic balance.1 Hypertrophy of
mesangial and proximal tubular cells is an early hallmark of
diabetes renal involvement.2–4 In fact, because the tubuloin-
terstitium comprises the bulk of the kidney, proximal tubular
hypertrophy is quantitatively responsible for the largest
component of renal enlargement in this condition.2,3 Recent
functional studies in the streptozotocin (STZ)-diabetic model
have shown that, in early diabetes, kidney growth causes a
primary increase in proximal tubule reabsorption, which is
responsible for diabetic renal hyperfiltration.5,6 This hyperfil-
tration state may contribute to proteinuria, structural renal
lesions, and the progression to chronic renal failure.2,4 As a
matter of fact, several observations indicate that the
development of diabetic glomerulosclerosis and tubulointer-
stitial fibrosis is always preceded by renal hypertrophy.2
Interactions among several cytokines and hemodynamic
agents are thought to be responsible for the renal changes
occurring in diabetes.2,7,8 However, the true molecular
mechanisms of diabetic nephropathy remain to be fully
characterized.
In the adult kidney, both parathyroid hormone-related
protein (PTHrP) and the PTH1 receptor (PTH1R) are
abundant throughout the renal parenchyma, including the
intrarenal vasculature.9–11 In the kidney, PTHrP appears to
modulate renal plasma flow and glomerular filtration rate,
and induces proliferative effects on both glomerular mesan-
gial and tubuloepithelial cells.12–18
Renal PTHrP is overexpressed in several experimental
nephropathies, including a rat model of tubulointerstitial
scarring after protein overload, associated with the development
of proteinuria.12,19 Although PTHrP upregulation appears to be
a common event associated with renal injury and repair, its
pathophysiological significance remains to be clarified.12 More-
over, no study has yet explored the putative involvement of
PTHrP in the pathophysiology of the diabetic kidney.
In the present study, we initially assessed the expression
and localization of PTHrP and PTH1R in the kidney of
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STZ-induced diabetic mice. We then explored the functional
consequences of chronic PTHrP overexpression in the
diabetic kidney using transgenic mouse strains overexpres-
sing PTHrP in the renal proximal tubule.20 Furthermore, the
effect of high-glucose medium on the expression of PTHrP
and PTH1R was analyzed in three mouse kidney cell lines:
tubuloepithelial MCT cells, mesangial cells, and conditionally
immortalized podocytes.
RESULTS
Renal functional parameters in diabetic mice
Diabetic mice exhibited hyperglycemia and developed renal
hypertrophy and increased urinary albumin excretion (UAE),
consistent with previous findings using a similar time
schedule in this model4,8,21,22 (Figure 1a and b). In these
mice, total plasma protein levels showed a tendency to
decrease (Figure 1c).
Expression and localization of PTHrP and PTH1R in the
diabetic mouse kidney
A single band corresponding to an apparent molecular
weight of 18 kDa was detected in the mouse kidney by PTHrP
antiserum C6, consistent with our recent findings20,23,24
(Figure 2, left). A similar band was observed in W256 tumor
extracts using this C-terminal antiserum, in agreement with
previous results using an N-terminal PTHrP antibody.25 This
molecular weight is similar to that reported for the
predominant PTHrP form isolated from other human and
animal tumors overexpressing this protein,26–28 and it is likely
to correspond to the single full-length PTHrP isoform
described in the mouse.9 Moreover, a significant increase in
this 18-kDa band was observed in the mouse kidney 2 weeks
after diabetes induction (Figure 3). Using immunoblotting
with antiserum C6, an increase in a single protein band with
a similar apparent molecular weight was also found in a rat
model of acute renal failure.24
In the mouse kidney, PTH1R was detected with the
antibody Ab-VII as a major 90-kDa band, consistent with our
findings in the rat kidney23,24 (Figure 2, right). This apparent
molecular weight is consistent with that reported for the
glycosylated receptor isolated from various tissues.29 This
antibody also revealed a minor band corresponding to 66 kDa
in mouse kidney extracts (Figure 2, right), which might be
the native nonglycosylated form of PTH1R.29 As preliminary
experiments showed that this minor band changed in
accordance with the major band, only the results of
densitometric analysis of the latter are shown below. Two
weeks after diabetes induction, a significant increase in the
PTH1R protein expression was found in the diabetic mouse
kidney (Figure 4). Renal levels of PTHrP and the PTH1R
protein peaked within 4–6 weeks of diabetes, decreasing
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Figure 1 | Renal functional parameters in experimental diabetes.
Index of renal hypertrophy (a), UAE (b), total plasma proteins (c), and
plasma creatinine (d) were evaluated at different time periods after
diabetes development in PTHrP-overexpressing mice (&) and their
normal littermates (’). aPo0.05, diabetic vs nondiabetic (at time ‘0’)
mice overexpressing PTHrP; bPo0.05, diabetic vs nondiabetic normal
littermates; *Po0.05, diabetic PTHrP-overexpressing mice vs diabetic
littermates.
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Figure 2 | Protein expression of PTHrP and PTH1R in the kidney
of PTHrP-overexpressing mice and their normal littermates.
Representative autoradiograms corresponding to Western blot
analysis of both PTHrP (using antiserum C6) (left) and PTH1R (using
antibody Ab-VII) (right) in the kidney of normal and PTHrP-
overexpressing transgenic mice (TG) in basal conditions. A minor
66-kDa band was detected with the latter antibody. Walker 256
(W256) tumor protein extracts (WT) were used as a positive control
for PTHrP. Antiserum C6 was replaced by preimmune serum, as a
negative control for PTHrP (middle panel).
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Figure 3 | Renal PTHrP protein expression in experimental
diabetes. Total protein was isolated from the mouse kidney at
different time periods after the development of diabetes. Auto-
radiograms and densitometric analysis corresponding to changes in
PTHrP protein by Western blot (using antiserum C6) in PTHrP-
overexpressing mice (&) and their normal littermates (’) are shown.
PTHrP protein levels were corrected to those of actin. AU: arbitrary
units.aPo0.05; bPo0.01, diabetic vs the corresponding nondiabetic
controls. Renal PTHrP protein levels in PTHrP-overexpressing mice
were significantly (Po0.05) higher than in their normal (nondiabetic)
littermates and unchanged by diabetes for the time period studied.
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thereafter, but remained over control values throughout the
study. Moreover, PTHrP levels were two-fold higher in the
renal cortex than in renal medulla in diabetic mice (Po0.05;
n¼ 6), but were similar in both cortex and medulla in
nondiabetic mice (not shown).
In the kidney of nondiabetic animals, PTHrP immuno-
staining (using antiserum C6) was present in the tubular
epithelium, whereas PTH1R staining was mainly observed in
the basolateral membrane of tubular cells (Figure 5b and d).
No positivity for either PTHrP or PTH1R was detected
within the glomerulus in these mice. By contrast, 6 weeks
after diabetes induction, the mouse kidney – showing a
normal morphology – displayed an intense staining in most
glomeruli for both PTHrP (1771/20 glomeruli, n¼ 5) and
PTH1R (1571/20 glomeruli, n¼ 5) (Figure 5c and e). In
addition, proximal and distal tubules (identified by morpho-
logical criteria) of diabetic mice showed a remarkable nuclear
immunolocalization of PTHrP not observed in the nondia-
betic animals (Figure 5b and c). Moreover, by using double
staining, an intense PTHrP immunofluorescence was found
in the tubular cell nucleus in the mouse diabetic, but not
nondiabetic, kidney with either PTHrP antiserum used, C6
(not shown) or C13 (Figure 6). No nuclear staining was
observed for PTH1R in these mice (Figure 6).
Outcome of diabetic nephropathy in PTHrP-overexpressing
mice
To explore the functional consequences of PTHrP upregu-
lation in the diabetic mouse kidney, we used transgenic mice
overexpressing PTHrP in the renal proximal tubule.20 In
these animals, the high renal PTHrP protein levels were
unchanged by diabetes (Figure 3). However, a diabetes-
related increase in renal PTH1R protein occurred in these
mice, although it was lower than that in their diabetic
littermates (Figure 3). Diabetes in PTHrP-overexpressing
mice was also associated with positive staining for both
PTHrP and PTH1R in the glomerulus, and for PTHrP in the
tubular cell nucleus (not shown).
After diabetes induction, PTHrP-overexpressing mice
progressively developed a significant increase in the renal
hypertrophy index and UAE, and had lower total plasma
protein values, compared to their normal littermates (Figure
1a–c). No changes in plasma creatinine occurred in diabetic
mice throughout the study (Figure 1d).
Using logistic regression analysis, renal PTHrP protein
levels were highly associated with UAE values in all diabetic
mice included in the study (Po0.01; n¼ 49). Similarly, a
significant association (Po0.01) was found between the renal
PTH1R levels and UAE in these mice (Table 1).
The effect of high glucose on PTHrP and the PTH1R protein in
mouse kidney cells
We next examined the effect of high glucose on the
expression of PTHrP and PTH1R in several renal cell lines
in vitro. Similar to findings in whole mouse kidney extracts, a
single band corresponding to 18 kDa was detected by
antiserum C6 in the three cell lines studied (Figure 7, left).
In addition, a single 66-kDa band was observed with the
antibody Ab-IV in these cell lines (Figure 7, right).
Differences in the specificity between this antibody and
antibody Ab-VII might account for their relative efficiency in
detecting either the 66-kDa or the 90-kDa band as observed
herein in vitro and in vivo, respectively.20,23,24
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Figure 4 | Renal PTH1R protein expression in experimental
diabetes. Total protein was isolated from the mouse kidney at
different time periods after the development of diabetes.
Autoradiograms and densitometric analysis corresponding to
changes in the PTH1R protein by Western blot (using antibody
Ab-VII) in PTHrP-overexpressing mice (&) and their normal
littermates (’) are shown. The PTH1R protein levels were
corrected to those of actin. AU: arbitrary units. aPo0.05; *Po0.01,
diabetic vs the corresponding nondiabetic controls; bPo0.05,
diabetic PTHrP-overexpressing mice vs diabetic littermates.
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Figure 5 | Immunostaining for PTHrP and PTH1R in the kidney of
diabetic mice at 6 weeks of diabetes. Kidney sections of
representative nondiabetic (b, d) and diabetic (c, e) animals, showing
immunolocalization of PTHrP (by using antiserum C6) (b, c) or PTH1R
(by using antibody Ab-VII) (d, e) in the glomerulus of diabetic mice
are shown. (a) Negative control without primary antibody. Original
magnification  250.
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High glucose induced an upregulation of PTHrP and
PTH1R protein at 24 h in MCT cells (Figure 8) and in both
glomerular cell lines (Figures 9 and 10). Losartan abolished
this PTHrP protein overexpression only in MCT cells and
podocytes (Figures 8–10), whereas it failed to affect the
PTH1R protein upregulation by high glucose in all cells
studied (Figures 8–10).
DISCUSSION
Renal PTHrP and angiotensin-converting enzyme genes
are upregulated in several experimental nephropa-
thies.12,16,18,19,23,24,30 Recently, we found that AT1 receptor
blockade in rats with acute renal failure was associated with
improved tubular damage and renal function related to a lack
of PTHrP upregulation.23,24 In renal tubuloepithelial cells,
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Figure 6 | PTHrP, but not PTH1R, localizes into the nucleus of the
renal tubules in the mouse kidney at 6 weeks of diabetes. Kidney
sections of representative nondiabetic (a, g) and diabetic (d, j) mice
showing immunostaining for either PTHrP (using antiserum C13)
(a, d) or PTH1R (using antibody Ab-IV) (g, j) are shown. Immunolo-
calization of both PTHrP and PTH1R was assessed by double staining,
for the nucleus (with propidium iodide; red) (b, e, h, k), and a
fluorescein isothiocyanate-labeled IgG (green) for either PTHrP
(a, d) or PTH1R (g, j) detection. The overlaid images in red and green
yielding an orange tone confirmed the presence of intense PTHrP
fluorescence in the nucleus of tubular cells in the mouse diabetic
kidney (f), but not in the nondiabetic mice (c). Similar results were
obtained with antiserum C6 (data not shown). By using this
maneuver, no nuclear staining was observed for PTH1R in either
nondiabetic (g, i) or diabetic mice (j, l).
Table 1 | Association between proteinuria and the PTHrP/
PTH1R system, and other biological parameters in diabetic
mice
Variable OR CI (95%)
a. Univariate analysis
PTH1R 5.8 1.8–17.8
PTHrP 6.2 2.2–17.3
Diuresis 4.1 1.4–12.1
Creatinine 3.4 1.2–9.4
Weight 1.1 0.4–3.2
Cholesterol 0.5 0.2–1.3
Glucose 2.2 0.8–5.3
b. Multivariate logistic regression analysis
PTH1R 16.8 2.3–124.9
PTHrP 6.7 1.0–43.5
Diuresis 9.0 1.3–64
Constant 0.06
CI, confidence interval; PTH1R, parathyroid hormone 1 receptor; PTHrP, parathyroid
hormone-related protein; OR, odds ratio.
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Figure 7 | Western blot analysis of PTHrP and PTH1R in mouse
renal cell lines. Representative autoradiograms corresponding to
Western blot analysis of both PTHrP (using antiserum C6) (left) and
PTH1R (using antibody Ab-IV) (right) in mouse kidney cell lines in
basal conditions: podocytes (P), mesangial cells (MMC), and cortical
tubule cells (MCT). Walker 256 (W256) tumor protein extracts (WT)
were used as a positive control for PTHrP.
PTHrP
a b
Actin
250
200
150
AU 100
50
0
HG − − + +
− + − −
− − − +
Mannitol
Losartan
HG − − + +
− + − −
− − − +
Mannitol
Losartan
250
200
150
AU 100
50
0
*
,a
PTH1R
Actin
*
Figure 8 | Induction of PTHrP and the PTH1R protein expression
by high glucose in MCT cells. Cells were cultured with or without
high-glucose (25 mM) medium (or the same concentration of
mannitol), in the presence or absence of 10 mM losartan, for 24 h.
Autoradiograms and densitometric analysis corresponding to
changes in PTHrP (a) and the PTH1R (b) protein levels by Western
blot (using antiserum C6 and antibody Ab-IV, respectively) are shown.
PTHrP and the PTH1R protein levels were corrected to those of actin
(n¼ 4). HG: high glucose; AU: arbitrary units. *Po0.05, compared
to normal glucose medium; aPo0.05, compared to HG
mediumþ losartan.
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angiotensin II (Ang II) interaction with AT1 receptors
activates mitogen-activated protein kinase and the transcrip-
tion factor cAMP-responsive element binding protein,
leading to increased PTHrP expression.24 Thus, PTHrP
appears to exert a reciprocal control on, or recapitulate,
some Ang II effects in the damaged kidney.
We presently used the STZ model, which is considered as
the ‘work horse’ for experimental studies in diabetic
nephropathy,31,32 a condition associated with angiotensin-
converting enzyme and mitogen-activated protein kinase
activation.2,6 Consistent with previous findings in this
model,4,8,21,22 diabetic mice developed renal hypertrophy
and an increase in UAE throughout this study. We found that
both PTHrP and the PTH1R protein were upregulated in the
diabetic mouse kidney. However, this increase in PTH1R was
partly blunted in PTHrP-overexpressing mice, suggesting that
homologous downregulation of this receptor, as observed in
these mice after acute renal failure,20 may counteract in part
the PTH1R upregulation in the diabetic kidney.
An intense immunostaining for both PTHrP and PTH1R
within the glomerular capillary tuft was found in the mouse
kidney but only in diabetic mice. The presence of PTHrP has
been previously disclosed in the glomerulus in frozen and
paraffin-embedded renal sections in rats and rabbits.10,16,19
Glomerular PTH1R mRNA has also been found by in situ
hybridization in frozen sections from normal rat glomeruli.33
Thus, the immunohistochemistry method used might require
a high protein expression of PTHrP and PTH1R – as that
found in diabetic animals – to be detected.
We found that diabetic mice, in contrast to nondiabetic
animals, had a remarkable nuclear staining for PTHrP in the
renal tubules. The mechanism of PTHrP internalization into
the nucleus of tubular cells is currently unknown. The
present findings, however, make it unlikely that such
mechanism involves PTH1R, but rather the nuclear localiza-
tion signal domain in the 88–106 region of the PTHrP
molecule.34,35 The antisera used in our immunolocalization
studies, recognizing two different C- and N-terminal
epitopes, seem to be similarly efficient in detecting full-
length PTHrP (containing nuclear localization signal do-
main) in the nucleus. Consistent with the PTHrP/PTH1R
system upregulation in experimental diabetic nephropathy,
high glucose was found to stimulate this system in
glomerular and tubuloepithelial cells in vitro.
Collectively, our present findings indicate that hyper-
glycemia should be added to the increasing list of renal
pathophysiological conditions associated with an altered
PTHrP/PTH1R system. These results also suggest that PTHrP
could act in an autocrine/paracrine as well as an intracrine
fashion in the diabetic mouse kidney.
In the present study, Ang II activation, which is known to
occur in the diabetic kidney,2,7 might have triggered the renal
PTHrP/PTH1R system, as observed in acute renal failure.24
In fact, losartan inhibited the high-glucose induction of
PTHrP in both tubuloepithelial MCT and mouse glomerular
cells. However, our findings also suggest that an AT1-
independent mechanism might be responsible for the PTH1R
upregulation induced by high glucose in these cells. In this
regard, Ang II infusion into normal rats increased PTHrP and
the PTH1R immunostaining in the renal parenchyma, but
this vasoactive agent failed to affect the PTH1R protein in rat
mesangial and MCT cells in vitro.23 Thus, definite conclu-
sions about the putative role of Ang II or other unidentified
hyperglycemia-related factors in the PTH1R expression in the
mouse diabetic kidney cannot be made at present.
Our findings demonstrate that diabetic PTHrP-over-
expressing mice, in comparison to their control littermates,
have increased renal hypertrophy. Although the mechanisms
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Figure 9 | Induction of PTHrP and the PTH1R expression by high
glucose in mouse mesangial cells. Cells were cultured with or
without high-glucose (25 mM) medium (or the same concentration of
mannitol), in the presence or absence of 10 mM losartan, for 24 h.
Autoradiograms and densitometric analysis corresponding to
changes in PTHrP (a) and the PTH1R (b) protein levels by Western
blot (using antiserum C6 and antibody Ab-IV, respectively) are shown.
PTHrP and the PTH1R protein levels were corrected to those of actin
(n¼ 4). HG: high glucose; AU: arbitrary units. *Po0.05, compared to
normal-glucose medium.
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Figure 10 | Induction of PTHrP and the PTH1R expression by high
glucose (25 mm) in mouse podocyte cells. Cells were cultured with
or without high-glucose (25 mM) medium (or the same concentration
of mannitol), in the presence or absence of 10 mM losartan, for 24 h.
Autoradiograms and densitometric analysis corresponding to
changes in PTHrP (a) and the PTH1R (b) protein levels by Western
blot (using antiserum C6 and antibody Ab-IV, respectively) are shown.
PTHrP and the PTH1R protein levels were corrected to those of actin
(n¼ 4). HG: high glucose; AU: arbitrary units. *Po0.05, compared to
normal-glucose medium; aPo0.05, compared to HG med-
iumþ losartan.
Kidney International (2006) 69, 2171–2178 2175
A Izquierdo et al.: PTHrP and diabetic nephropathy outcome o r i g i n a l a r t i c l e
of diabetic renal hypertrophy are still ill-defined, Ang II and
transforming growth factor-b have important roles in this
condition.2 Transforming growth factor-b is upregulated by
high glucose and can transform a mitogenic stimulus into
hypertrophy in tubuloepithelial cells.36–39 Of note, PTHrP is a
mitogen for proximal tubular cells, and has shown to act as a
downstream effector of transforming growth factor-b at least
in some cell systems.17,40–42 As recently suggested by Clemens
et al.,9 PTHrP also appears to be an important regulatory
factor of glomerular hemodynamics, and might participate in
the pathophysiology of glomerular hyperfiltration. Collec-
tively, these data strongly suggest that PTHrP could be
involved in the mechanisms of renal hypertrophy in diabetes.
We also found that diabetic PTHrP-overexpressing mice
have higher UAE and lower total plasma protein levels than
their diabetic control littermates. Furthermore, there was a
six-fold increase in the risk of developing proteinuria in those
mice with the higher PTHrP and PTH1R levels, according to
the logistic regression analysis. PTHrP is a potent vasorelax-
ant and can interact with vasoactive factors affecting
glomerular hemodynamics and permeability.9,10,13,14 These
effects seem to occur partly through interaction with PTH1R
and subsequent activation of the nitric oxide/cyclic guanosine
monophosphate pathway.10 In addition, PTHrP has pro-
inflammatory/profibrogenic features in some cells.43–45 Inter-
estingly, an increase in nitric oxide and various proinflam-
matory cytokines appear to play critical roles in the diabetic
kidney.1,46,47
It is thus tempting to speculate that any of these
mechanisms would contribute to the relationship between
the PTHrP/PTH1R system and proteinuria in this diabetic
model. In any case, our data indicate that changes in the renal
PTHrP/PTH1R system have predictive value on the early
development of proteinuria in mice. Although the STZ
model has limitations for assessing long-term histomorpho-
logical changes in the diabetic kidney,31,32 our findings might
have pathophysiological implications, as the amount of
proteinuria is a reliable predictor of diabetic nephro-
pathy.48,49
In conclusion, the present results demonstrate that the
renal PTHrP/PTH1R system is upregulated during STZ-
induced diabetes in mice, and this upregulation appears to
affect adversely the outcome of diabetic renal disease. Our
findings also suggest that Ang II might have a role in PTHrP
upregulation in this setting.
MATERIALS AND METHODS
Experimental procedure
We used two types of mice, normal CD-1 mice and PTHrP-
overexpressing mice, generously supplied by Professor AF Stewart
and Dr A Garcı´a-Ocan˜a (University of Pittsburg School of Medicine,
Pittsburg, PA, USA).20 The renal specificity of the transgene was
conferred by the g-glutamyl transpeptidase-l promoter, mainly
expressed in the renal proximal tubule. PTHrP-overexpressing mice
were generated by breeding two types of transgenic mice: one
containing a g-glutamyl transpeptidase-l promoter fragment
upstream of a tetracycline transactivator fusion protein – which
functions as a strong transcription activator; and the other with a
PTHrP complementary DNA placed under the control of a
tetracycline operator construct. Transgene-bearing founders were
continuously outbred to normal CD-1 mice to generate hemi-
zygotes. Genotyping of these mice was performed by tail DNA PCR,
as described.20 In all of the experiments described below, adult mice
(4–8 months old) were used, and the results obtained with PTHrP-
overexpressing transgenic mice were compared with those using
their corresponding normal littermates.20,50 All studies were
performed with the approval of and in accordance with guidelines
established by Institutional Animal Care and Use Committees at the
University of Alcala´ and Fundacio´n Jime´nez Dı´az.
Mice were housed in a temperature-controlled room (21721C)
on a 14/10 h light/dark cycle under pathogen-free conditions and
with free access to food and water. Diabetes was induced by three
consecutive daily intraperitoneal injections of STZ (Sigma, St Louis,
MO, USA), 65 mg/kg body weight in citrate buffer, pH 4.5 (vehicle).
This is a previously reported model of early diabetic nephropathy
characterized by renal hypertrophy and increased UAE during the
first month of diabetes.21,22 After the last STZ injection, induction of
diabetes was confirmed by measurement of blood glucose levels.
Forty-nine diabetic animals (25 PTHrP-overexpressing mice and 24
normal littermates), with blood glucose 4300 mg/dl, were included
in the study. Animals were killed under ether anesthesia 2, 4, 6, and
8 weeks following the development of diabetes (n¼ 6–7, at each time
period). Another group (n¼ 6–10) of weight-matched PTHrP-
overexpressing mice or their corresponding normal littermates
received the same volume of vehicle and were used as nondiabetic
controls.
Animals were individually housed in metabolic cages with free
access to tap water, and 24-h urine was collected for protein
measurement by the sulfosalicylic acid method, as previously
reported.51 Blood was taken by cardiac puncture under ether
anesthesia, and plasma glucose was determined by the glucose oxidase
technique.52 One kidney of each animal was removed, weighed, frozen
in liquid nitrogen, and stored at 801C for subsequent total protein
extraction. In some cases, the kidneys were dissected, the capsule
removed, and the cortex – separated from the medulla – was frozen as
described. The remaining kidney of each animal was fixed in 4%
buffered p-formaldehyde for morphological and immunohistochem-
istry studies. The degree of renal hypertrophy was expressed as an
index, the ratio of kidney weight to total body weight.
Histology and immunohistochemistry
Fixed renal tissue sections were dehydrated by graded ethanols and
xylene, and then embedded in paraffin. Paraffin-embedded tissue
sections (4mm) were stained with hematoxylin. PTHrP immuno-
staining was performed using rabbit polyclonal anti-PTHrP
antiserum C6, recognizing the highly conserved C-terminal epitope
107–111 in the intact PTHrP molecule,17,53 as described.23,24 For the
PTH1R staining, we tested two well-characterized affinity-purified
polyclonal antibodies to this receptor: one recognizing its extra-
cellular domain (Ab-VII; Covance, Berkeley, CA, USA), which has
been extensively used in previous studies;18–20,23 and antibody Ab-IV
(Covance), directed against the region 248–262 in the PTH1R
molecule, contributing to receptor activation.20,54 We found that
both antibodies had similar sensitivity to detect this receptor in the
mouse kidney, by immunohistochemistry. Some kidney samples
were incubated without primary antibody or with nonimmune
rabbit serum as negative controls.
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The number of glomeruli showing capillary staining for both
PTHrP and PTH1R per 20 glomeruli without selection was counted
for each mouse.18 Histological evaluations were performed by two
independent observers in a blinded fashion. The final score was the
mean of the two evaluations.
To assess putative changes in the localization pattern of PTHrP
and PTH1R in the diabetic mouse kidney, renal tissue samples from
diabetic and nondiabetic mice were permeabilized with 0.1% Triton
X-100 in phosphate-buffered saline for 30 min at 371C. After
blocking with 1.5% normal goat serum, the samples were incubated
overnight at 41C with the following primary antibodies: PTHrP
antiserum C6 and PTHrP antiserum C13 recognizing an N-terminal
epitope in the intact PTHrP molecule and also the PTHrP (1–36)
fragment,53 each at 1:100 dilution; and the PTH1R antibody Ab-IV,
at 1:250 dilution. Then, fluorescein isothiocyanate-conjugated goat
anti-rabbit IgG (Sigma), at 1:200 dilution, was added for 30 min.
After washing, samples were counterstained with propidium iodide
to detect cell nuclei, and mounted with Mowiol (Calbiochem, San
Diego, CA, USA). Immunofluorescence analysis was performed with
a Leica DM-IRB confocal microscope.24
Cell cultures
We used three well-established mouse kidney cell lines – cortical
tubule MCT cells, mesangial cells, and podocytes – to evaluate the
effect of high glucose on the PTHrP/PTH1R system in vitro. MCT
cells were grown in RPMI 1640 with 10% fetal bovine serum and
antibiotics in 5% CO2 at 371C, as described.
23 Mouse mesangial cells
(ATCC CRL-1927) were cultured in Dulbecco’s modified Eagle’s
medium and Ham’s F12 medium (3:1, v/v) with 5% fetal bovine
serum.55
Conditionally immortalized mouse podocytes (a generous gift
from Dr Herman Pavensta¨dt, University Hospital of Freiburg,
Freiburg, Germany) were cultured as reported.56,57 Podocytes were
cultured on type I collagen (Sigma) and grown in RPMI 1640
medium with 5% fetal bovine serum and antibiotics, supplemented
with 10 U/ml recombinant interferon-g to enhance T-antigen
expression, at 331C (permissive conditions). To induce differentia-
tion, podocytes were maintained on type I collagen at 371C without
interferon-g (nonpermissive conditions).
Cells between passages 10 and 16 were used in all experiments.
MCT and mesangial cells were serum-depleted, and podocytes were
switched to 1% fetal bovine serum-containing medium for 24 h
before experiments. The cells were then treated with 25 mM glucose
(or mannitol) for 24 h,58,59 in the presence or absence of the AT1
receptor blocker losartan (MSD, Madrid, Spain).23,24
Western blot analysis of PTHrP and PTH1R
Proteins were isolated from either mouse kidney homogenates or
cultured cells, using a standard procedure (TriReagent; Molecular
Research Center, Cincinnati, OH, USA). Fifteen micrograms of
protein from total kidney (or kidney cortex) or cultured renal cells,
estimated by the Bradford’s method,60 were separated on 10–15%
sodium dodecyl sulfate-polyacrylamide gels and transferred to
polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA,
USA). The membranes were blocked using 100 mM Tris, 150 mM
NaCl, pH 7.5, and 0.1% Tween 20 (TTBS) with 5% bovine serum
albumin (PTHrP) or 5% defatted milk (PTH1R). They were then
incubated overnight at 41C with PTHrP antiserum C6, at 1/2000
dilution, as reported,20,23,24 and the anti-PTH1R antibodies Ab-VII
or Ab-IV, at 1/200 and 1/1000 dilution, respectively, in TTBS. In the
kidney, Ab-VII antibody detects mainly a 90-kDa band,23,24 whereas
a single 66-kDa band was revealed with the Ab-IV antibody,20 in
agreement with the manufacturer’s information (website: www.
crpinc.com). Walker 256 (W256) tumor protein extracts were used
as a positive control for PTHrP.25 An anti-actin antibody (Sigma),
at 1:500 dilution, was used as a loading control. Following
incubation with biotinylated anti-rabbit IgG (or peroxidase-
conjugated anti-rabbit IgG), bands were detected with 3,30-diamino-
benzidine (DAKO, Glostrup, Denmark) or ECL chemiluminescence
(Amersham, Buckinghamshire, UK). Blots were analyzed by
densitometric scanning. Densitometric values were normalized
against those of actin.
Statistical analysis
All results are expressed as mean7s.e.m. Statistical significance
(Po0.05) was assessed by Kruskal–Wallis test or Mann–Whitney
test, when appropriate. To assess the association between PTHrP and
the PTH1R protein levels (by Western analysis) and UAE,
quantitative values corresponding to all diabetic animals included
throughout the study (n¼ 49) were converted to qualitative
parameters by grouping the upper – over the median – and the
lower –under the median –values. Then, univariate and multivariate
logistic regression analysis was performed. The SPSS 9.0 statistical
package (SPSS Inc., Chicago, IL, USA) was used.
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